Please wait a minute...

Frontiers of Medicine

Front Med    2013, Vol. 7 Issue (1) : 60-64     DOI: 10.1007/s11684-013-0246-6
Primary hypertrophic osteoarthropathy: an update
Zeng Zhang1,2, Changqing Zhang2(), Zhenlin Zhang1()
1. Metabolic Bone Disease and Genetic Research Unit, Department of Osteoporosis and Bone Diseases, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233, China; 2. Department of Orthopedic Surgery, Shanghai Jiao Tong University Affliated Sixth People’s Hospital, Shanghai 200233, China
Download: PDF(159 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Digital clubbing, which has been recognized as a sign of systemic disease, is one of the most ancient diseases. However, the pathogenesis of clubbing and hypertrophic osteoarthropathy has hitherto been poorly understood. The study of a clinically indistinguishable idiopathic form (primary hypertrophic osteoarthropathy, PHO) provides an opportunity to understand the pathogenesis of hypertrophic osteoarthropathy. Current advances in the study of PHO are discussed. The impaired metabolism of prostaglandin E2 (PGE2) plays a central role in its pathogenesis.

Keywords digital clubbing      primary hypertrophic osteoarthropathy      prostaglandin E2 (PGE2)     
Corresponding Authors: Zhang Changqing,; Zhang Zhenlin,   
Issue Date: 05 March 2013
 Cite this article:   
Zeng Zhang,Changqing Zhang,Zhenlin Zhang. Primary hypertrophic osteoarthropathy: an update[J]. Front Med, 2013, 7(1): 60-64.
E-mail this article
E-mail Alert
Articles by authors
Zeng Zhang
Changqing Zhang
Zhenlin Zhang
Fig.1  Clinical features. (A) Digital clubbing. (B) Marked skin thickening. (C) Periosteal overgrowth of long bones.
Fig.1  Clinical features. (A) Digital clubbing. (B) Marked skin thickening. (C) Periosteal overgrowth of long bones.
1 Castori M, Sinibaldi L, Mingarelli R, Lachman RS, Rimoin DL, Dallapiccola B. Pachydermoperiostosis: an update. Clin Genet 2005; 68(6): 477-486
doi: 10.1111/j.1399-0004.2005.00533.x pmid:16283874
2 Friedreich N. Hyperostose des gesammten skelettes. Virchows Arch 1868; 43(1): 83-87
doi: 10.1007/BF02117271
3 Touraine A, Solente G, Gole L. Un syndrome nosteodermopathique: la pachydermie plicaturee avec pachyperiostose des extremites. Presse Med 1935; 43: 1820-1824
4 Jajic I. Epidemiology of hypertrophic osteoarthropathy. Clin Exp Rheumatol 1992; 10(Suppl 7): 13
5 Oikarinen A, Palatsi R, Kylm?niemi M, Keski-Oja J, Risteli J, Kallioinen M. Pachydermoperiostosis: analysis of the connective tissue abnormality in one family. J Am Acad Dermatol 1994; 31(6): 947-953
doi: 10.1016/S0190-9622(94)70262-4 pmid:7962775
6 Harbison JB, Nice CM Jr. Familial pachydermoperiostosis presenting as an acromegaly-like syndrome. Am J Roentgenol Radium Ther Nucl Med 1971; 112(3): 532-536
7 Rimoin DL. Pachydermoperiostosis (Idiopathic Clubbing and Periostosis): genetic and physiologic considerations. N Engl J Med 1965; 272(18): 923-931
doi: 10.1056/NEJM196505062721801 pmid:14274448
8 Currarino G, Tierney RC, Giesel RG, Weihl C. Familial idiopathic osteoarthropathy. Am J Roentgenol Radium Ther Nucl Med 1961; 85: 633-644
9 Chamberlain DS, Whitaker J, Silverman FN. Idiopathic Osteoarthropathy and Cranial Defects in Children (Familial Idiopathic Osteoarthropathy). Am J Roentgenol Radium Ther Nucl Med 1965; 93: 408-415
10 Guyot-Drouot MH, Solau-Gervais E, Cortet B, Deprez X, Chastanet P, Cotten A, Delcambre B, Flipo RM. Rheumatologic manifestations of pachydermoperiostosis and preliminary experience with bisphosphonates. J Rheumatol 2000; 27(10): 2418-2423
11 Martinez-Lavin M. Miscellaneous non-inflammatory musculoskeletal conditions. Pachydermoperiostosis . Best Pract Res Clin Rheumatol 2011; 25(5): 727-734
doi: 10.1016/j.berh.2011.10.019 pmid:22142750
12 Sinha GP, Curtis P, Haigh D, Lealman GT, Dodds W, Bennett CP. Pachydermoperiostosis in childhood. Br J Rheumatol 1997; 36(11): 1224-1227
doi: 10.1093/rheumatology/36.11.1224 pmid:9402870
13 Uppal S, Diggle CP, Carr IM, Fishwick CW, Ahmed M, Ibrahim GH, Helliwell PS, Latos-Bieleńska A, Phillips SE, Markham AF, Bennett CP, Bonthron DT. Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy. Nat Genet 2008; 40(6): 789-793
doi: 10.1038/ng.153 pmid:18500342
14 Zhang Z, Xia W, He J, Zhang Z, Ke Y, Yue H, Wang C, Zhang H, Gu J, Hu W, Fu W, Hu Y, Li M, Liu Y. Exome sequencing identifies SLCO2A1 mutations as a cause of primary hypertrophic osteoarthropathy. Am J Hum Genet 2012; 90(1): 125-132
doi: 10.1016/j.ajhg.2011.11.019 pmid:22197487
15 Diggle CP, Parry DA, Logan CV, Laissue P, Rivera C, Restrepo CM, Fonseca DJ, Morgan JE, Allanore Y, Fontenay M, Wipff J, Varret M, Gibault L, Dalantaeva N, Korbonits M, Zhou B, Yuan G, Harifi G, Cefle K, Palanduz S, Akoglu H, Zwijnenburg PJ, Lichtenbelt KD, Aubry-Rozier B, Superti-Furga A, Dallapiccola B, Accadia M, Brancati F, Sheridan EG, Taylor GR, Carr IM, Johnson CA, Markham AF, Bonthron DT. Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosis. Hum Mutat 2012; 33(8): 1175-1181
doi: 10.1002/humu.22111 pmid:22553128
16 Seifert W, Kühnisch J, Tüysüz B, Specker C, Brouwers A, Horn D. Mutations in the prostaglandin transporter encoding gene SLCO2A1 cause primary hypertrophic osteoarthropathy and isolated digital clubbing. Hum Mutat 2012; 33(4): 660-664
doi: 10.1002/humu.22042 pmid:22331663
17 Busch J, Frank V, Bachmann N, Otsuka A, Oji V, Metze D, Shah K, Danda S, Watzer B, Traupe H, Bolz HJ, Kabashima K, Bergmann C. Mutations in the prostaglandin transporter SLCO2A1 cause primary hypertrophic osteoarthropathy with digital clubbing. J Invest Dermatol 2012; 132(10): 2473-2476
doi: 10.1038/jid.2012.146 pmid:22696055
18 Bergmann C, Wobser M, Morbach H, Falkenbach A, Wittenhagen D, Lassay L, Ott H, Zerres K, Girschick HJ, Hamm H. Primary hypertrophic osteoarthropathy with digital clubbing and palmoplantar hyperhidrosis caused by 15-PGHD/HPGD loss-of-function mutations. Exp Dermatol 2011; 20(6): 531-533
doi: 10.1111/j.1600-0625.2011.01248.x pmid:21426412
19 Sinibaldi L, Harifi G, Bottillo I, Iannicelli M, El Hassani S, Brancati F, Dallapiccola B. A novel homozygous splice site mutation in the HPGD gene causes mild primary hypertrophic osteoarthropathy. Clin Exp Rheumatol 2010; 28(2): 153-157
20 Diggle CP, Carr IM, Zitt E, Wusik K, Hopkin RJ, Prada CE, Calabrese O, Rittinger O, Punaro MG, Markham AF, Bonthron DT. Common and recurrent HPGD mutations in Caucasian individuals with primary hypertrophic osteoarthropathy. Rheumatology (Oxford) 2010; 49(6): 1056-1062
doi: 10.1093/rheumatology/keq048 pmid:20299379
21 Tariq M, Azeem Z, Ali G, Chishti MS, Ahmad W. Mutation in the HPGD gene encoding NAD+ dependent 15-hydroxyprostaglandin dehydrogenase underlies isolated congenital nail clubbing (ICNC). J Med Genet 2009; 46(1): 14-20
doi: 10.1136/jmg.2008.061234 pmid:18805827
22 Sasaki T, Niizeki H, Shimizu A, Shiohama A, Hirakiyama A, Okuyama T, Seki A, Kabashima K, Otsuka A, Ishiko A, Tanese K, Miyakawa S, Sakabe J, Kuwahara M, Amagai M, Okano H, Suematsu M, Kudoh J. Identification of mutations in the prostaglandin transporter gene SLCO2A1 and its phenotype-genotype correlation in Japanese patients with pachydermoperiostosis. J Dermatol Sci 2012; 68(1): 36-44
doi: 10.1016/j.jdermsci.2012.07.008 pmid:22906430
23 Ursing B. Pachydermoperiostosis. Acta Med Scand 1970; 188(3): 157-160
24 Cantatore FP, Mancini L, Ingrosso AM, Carrozzo M. Pachydermoperiostosis: dermatological, neurological and radiological observations. Clin Rheumatol 1995; 14(6): 705-707
doi: 10.1007/BF02207941 pmid:8608693
25 Jajic I, Jajic Z, Grazio S. Minor but important symptoms and signs in primary hypertrophic osteoarthropathy. Clin Exp Rheumatol 2001; 19(3): 357-358
26 Saigal R, Kansal A, Mittal M, Singh Y, Ram H. Pachydermoperiostosis with myelofibrosis and empty sella. J Assoc Physicians India 2010; 58: 253-255
27 Martinez-Lavin M. Exploring the cause of the most ancient clinical sign of medicine: finger clubbing. Semin Arthritis Rheum 2007; 36(6): 380-385
doi: 10.1016/j.semarthrit.2006.11.004 pmid:17276498
28 de Vernejoul MC, Kornak U. Heritable sclerosing bone disorders: presentation and new molecular mechanisms. Ann N Y Acad Sci 2010; 1192(1): 269-277
doi: 10.1111/j.1749-6632.2009.05244.x pmid:20392246
29 Narayanan S, Mohamed Gani VM, Sundararaju V. Primary hypertrophic osteoarthropathy with hypertrophic gastropathy. J Clin Rheumatol 2010; 16(4): 190-192
doi: 10.1097/RHU.0b013e3181e04d80 pmid:20511980
30 Martínez-Lavín M. Digital clubbing and hypertrophic osteoarthropathy: a unifying hypothesis. J Rheumatol 1987; 14(1): 6-8
31 Dickinson CJ, Martin JF. Megakaryocytes and platelet clumps as the cause of finger clubbing. Lancet 1987; 2(8573): 1434-1435
doi: 10.1016/S0140-6736(87)91132-9 pmid:2891996
32 Watanabe O, Arimura K, Kitajima I, Osame M, Maruyama I. Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome. Lancet 1996; 347(9002): 702
doi: 10.1016/S0140-6736(96)91261-1 pmid:8596427
33 Soubrier M, Dubost JJ, Serre AF, Ristori JM, Sauvezie B, Cathebras P, Piette JC, Chapman A, Authier FJ, Gherardi RK. Growth factors in POEMS syndrome: evidence for a marked increase in circulating vascular endothelial growth factor. Arthritis Rheum 1997; 40(4): 786-787
doi: 10.1002/art.1780400430 pmid:9125266
34 Silveira LH, Martínez-Lavín M, Pineda C, Fonseca MC, Navarro C, Nava A. Vascular endothelial growth factor and hypertrophic osteoarthropathy. Clin Exp Rheumatol 2000; 18(1): 57-62
35 Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25(4): 581-611
doi: 10.1210/er.2003-0027 pmid:15294883
36 Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13(1): 9-22
37 Towler DA. Vascular biology and bone formation: hints from HIF. J Clin Invest 2007; 117(6): 1477-1480
doi: 10.1172/JCI32518 pmid:17549250
38 Olán F, Portela M, Navarro C, Gaxiola M, Silveira LH, Ruiz V, Martínez-Lavín M. Circulating vascular endothelial growth factor concentrations in a case of pulmonary hypertrophic osteoarthropathy. Correlation with disease activity. J Rheumatol 2004; 31(3): 614-616
39 Vazquez-Abad D, Martinez-Lavin M. Macrothrombocytes in the peripheral circulation of patients with cardiogenic hypertrophic osteoarthropathy. Clin Exp Rheumatol 1991; 9(1): 59-62
40 Nomura T, Lu R, Pucci ML, Schuster VL. The two-step model of prostaglandin signal termination: in vitro reconstitution with the prostaglandin transporter and prostaglandin 15 dehydrogenase. Mol Pharmacol 2004; 65(4): 973-978
doi: 10.1124/mol.65.4.973 pmid:15044627
41 Schuster VL. Prostaglandin transport. Prostaglandins Other Lipid Mediat 2002; 68- 69: 633-647
doi: 10.1016/S0090-6980(02)00061-8 pmid:12432949
42 Endo S, Nomura T, Chan BS, Lu R, Pucci ML, Bao Y, Schuster VL. Expression of PGT in MDCK cell monolayers: polarized apical localization and induction of active PG transport. Am J Physiol Renal Physiol 2002; 282(4): F618-F622
43 Cattral MS, Altraif I, Greig PD, Blendis L, Levy GA. Toxic effects of intravenous and oral prostaglandin E therapy in patients with liver disease. Am J Med 1994; 97(4): 369-373
doi: 10.1016/0002-9343(94)90305-0 pmid:7942940
44 Coggins KG, Latour A, Nguyen MS, Audoly L, Coffman TM, Koller BH. Metabolism of PGE2 by prostaglandin dehydrogenase is essential for remodeling the ductus arteriosus. Nat Med 2002; 8(2): 91-92
doi: 10.1038/nm0202-91 pmid:11821873
45 Chang HY, Locker J, Lu R, Schuster VL. Failure of postnatal ductus arteriosus closure in prostaglandin transporter-deficient mice. Circulation 2010; 121(4): 529-536
doi: 10.1161/CIRCULATIONAHA.109.862946 pmid:20083684
46 Martínez-Lavín M, Pineda C, Navarro C, Buendía A, Zabal C. Primary hypertrophic osteoarthropathy: another heritable disorder associated with patent ductus arteriosus. Pediatr Cardiol 1993; 14(3): 181-182
doi: 10.1007/BF00795652 pmid:8415225
47 Harada S, Nagy JA, Sullivan KA, Thomas KA, Endo N, Rodan GA, Rodan SB. Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts. J Clin Invest 1994; 93(6): 2490-2496
doi: 10.1172/JCI117258 pmid:8200985
48 Fabre JE, Nguyen M, Athirakul K, Coggins K, McNeish JD, Austin S, Parise LK, FitzGerald GA, Coffman TM, Koller BH. Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation. J Clin Invest 2001; 107(5): 603-610
doi: 10.1172/JCI10881 pmid:11238561
49 Nguyen S, Hojjati M. Review of current therapies for secondary hypertrophic pulmonary osteoarthropathy. Clin Rheumatol 2011; 30(1): 7-13
doi: 10.1007/s10067-010-1563-7 pmid:20936419
50 Jayakar BA, Abelson AG, Yao Q. Treatment of hypertrophic osteoarthropathy with zoledronic acid: case report and review of the literature. Semin Arthritis Rheum 2011; 41(2): 291-296
doi: 10.1016/j.semarthrit.2011.01.007 pmid:21435696
51 Tanaka H, Maehama S, Imanaka F, Sakai A, Abe K, Hamada M, Yamashita J, Kimura A, Imamura N, Fujimura K, Kuramoto A. Pachydermoperiostosis with myelofibrosis and anemia: report of a case of anemia of multifactorial causes and its improvement with steroid pulse and iron therapy. Jpn J Med 1991; 30(1): 73-80
doi: 10.2169/internalmedicine1962.30.73 pmid:1865580
52 Ninomiya S, Hara T, Tsurumi H, Kanemura N, Kasahara S, Ogawa Y, Seishima M, Hirose Y, Moriwaki H. Myelofibrosis successfully treated with prednisolone in a patient with pachydermoperiostosis. Intern Med 2011; 50(19): 2207-2211
doi: 10.2169/internalmedicine.50.5717 pmid:21963742
Full text